Trials / Completed
CompletedNCT03846427
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | Zanubrutinib at a dose of 160 mg orally twice a day (BID) |
Timeline
- Start date
- 2019-02-19
- Primary completion
- 2022-05-04
- Completion
- 2022-05-04
- First posted
- 2019-02-19
- Last updated
- 2024-10-26
- Results posted
- 2022-03-03
Locations
31 sites across 9 countries: United States, Australia, China, Czechia, France, Italy, New Zealand, South Korea, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03846427. Inclusion in this directory is not an endorsement.